Events
-
-
-
-
ENDO 2026: Women’s thyroid cancer risk may be linked to reproductive lifespan and hormone therapy
-
ASCO 2026: Lancet Commission predict shortfall of 100 million cancer care workers by 2050
-
ASCO 2026: CAPTURE trial delivers learnings for metastatic breast cancer treatment
-
ASCO 2026: Teclistamab extends survival, deepens remissions in relapsed multiple myeloma
-
ASCO 2026: Lancet Commission predict shortfall of 100 million cancer care workers by 2050
-
-
ASCO 2026: Teclistamab extends survival, deepens remissions in relapsed multiple myeloma
Gut bacteria from tree frogs: unexplored biodiversity could represent a treasure trove for novel medical technology
A research team of Prof. Eijiro Miyako at the Japan Advanced Institute of Science and Technology (JAIST)…
Valvular heart disease is common in cancer patients but interventions improve survival
Valvular heart disease, identified through cardiovascular imaging, is common in cancer patients. Interventions to treat…
Keeping the heart healthy increases longevity even after cancer
Being more physically active, following a balanced diet, not smoking, and keeping body weight and…
SABCS 2025: Mobile health tool may improve quality of life for adolescent and young adult breast cancer survivors
- SABCS 2025: Study solves a long-standing gap in metastatic breast cancer research and care: accurately measuring treatment response in patients with bone metastases
- SABCS 2025: Sentinel lymph node biopsy may be safely omitted in some patients with early-stage breast cancer
- MYC targeting by omomyc synergizes with PARP inhibition and potentiates antitumour response in preclinical models of triple-negative breast cancer
Encouraging patients to ask questions
How often do men with localised prostate cancer regret their treatment decisions? What practical support can be offered to men…
Depression and inflammation: A bad combo for lung cancer patients
- Rare non-small cell lung cancer with brain metastases responds to amivantamab monotherapy
- ASCO 2025: Molecular assay may help identify people with NSCLC who could benefit from adjuvant chemotherapy
- ASCO 2025: Addition of lurbinectedin to first-line maintenance treatment for small cell lung cancer prolongs survival, according to phase 3 trial
Poor, middle-aged Australians are more likely to die from cancer – and the gap is widening
Kadir Atalay, University of Sydney and Rebecca Edwards, University of Sydney A cancer diagnosis is frightening news for anyone. But…
JOIN THE ONCOLOGY NETWORK
If you would like even more free news articles, access to our exclusive HCP only content including the latest podcasts from The Oncology Podcast and our Industry Partner Podcasts (including links to all papers and show notes), along with all our other resources, head over to The Oncology Network and sign up - FREE forever for HCPs only.